We’re hiring post-docs! Join our lab on projects involving immunotherapy and therapy resistance and metastasis in cutaneous and uveal melanoma. Please DM if interested!
10.05.2025 11:49 — 👍 0 🔁 0 💬 0 📌 0We’re hiring post-docs! Join our lab on projects involving immunotherapy and therapy resistance and metastasis in cutaneous and uveal melanoma. Please DM if interested!
10.05.2025 11:49 — 👍 0 🔁 0 💬 0 📌 05/The project was only possible because of collaboration with the Van Allen lab, talented co-first authors Julia Schiantarelli, Mouadh Benamar, Jihye Park. I am grateful to patients who donated biopsy material and funding sources, including @melanomaresearch.bsky.social @danafarbernews.bsky.social
10.02.2025 16:08 — 👍 1 🔁 0 💬 1 📌 04/and a reduced capacity to activate cytotoxic T cells.
10.02.2025 16:08 — 👍 0 🔁 0 💬 1 📌 03/Strikingly, we found resistance-associated mutations in SEC24C and SEC24D in 3 patients. Melanoma cells engineered to express the SEC24C mutations observed in patients exhibit diminished STING signaling, including decreased Type I interferon production, antigen presentation
10.02.2025 16:06 — 👍 0 🔁 0 💬 0 📌 02/Over several years, we collected matched pre-treatment and post-resistance tumor biopsies in patients with metastatic melanoma who exhibited heterogeneous ICI responses to nominate additional mediators of acquired resistance.
10.02.2025 16:06 — 👍 0 🔁 0 💬 0 📌 01/Although some patients with metastatic melanoma experience durable responses to immune checkpoint inhibitors, most exhibit intrinsic or acquired resistance to these therapies.
10.02.2025 16:06 — 👍 0 🔁 0 💬 0 📌 0
Our paper on a new mechanism of resistance to immunotherapy in melanoma is now in print
@Cancer_Cell
with the @vanallenlab.bsky.social t.co/TCC4brc6yb